Eli Lilly posts promising PhIII migraine results, but settles into the pack in the last leg of the race to the FDA
Eli Lilly $LLY is lining up its application for its CGRP migraine drug galcanezumab after racking up a slate of date from three Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
